1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Gastric Cancer Partnering 2010-2015

Gastric Cancer Partnering 2010-2015

  • March 2015
  • -
  • Currentpartnering
  • -
  • 150 pages

The Gastric Cancer Partnering 2010-2015 report provides understanding and access to the gastric cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in gastric cancer partnering deals
Top gastric cancer deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Gastric Cancer Partnering 2010-2015 provides understanding and access to the gastric cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of gastric cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors gastric cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 40 links to online copies of actual gastric cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of gastric cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of gastric cancer technologies and products.

Report scope

Gastric Cancer Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to gastric cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in gastric cancer dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 40 gastric cancer deals and contract documents where available
The leading gastric cancer deals by value since 2010

In Gastric Cancer Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Gastric Cancer Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gastric cancer partnering

2.1. Introduction
2.2. Gastric cancer partnering over the years
2.3. Gastric cancer partnering by deal type
2.4. Gastric cancer partnering industry sector
2.5. Gastric cancer partnering by stage of development
2.6. Gastric cancer partnering by technology type

Chapter 3 - Average deal terms for Gastric cancer

3.1 Introduction
3.2 Average deal terms for Gastric cancer
3.3 Gastric cancer headline values with median calculation
3.4 Gastric cancer upfront values with median calculation
3.5 Gastric cancer milestone values with median calculation
3.6 Gastric cancer royalty rates with median calculation

Chapter 4 - Active Gastric cancer dealmakers

4.1. Introduction
4.2 Most active Gastric cancer dealmakers
4.3. Top Gastric cancer deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Gastric cancer dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Gastric cancer partnering since 2010
Figure 2: Gastric cancer dealmaking activity- 2010 to 2015
Figure 3: Gastric cancer partnering by deal type since 2010
Figure 4: Gastric cancer partnering by industry sector since 2010
Figure 5: Gastric cancer partnering by stage of development since 2010
Figure 6: Gastric cancer partnering by technology type since 2010
Figure 7: Gastric cancer deals with a headline value
Figure 8: Gastric cancer deals with upfront payment values
Figure 9: Gastric cancer deals with milestone payments
Figure 10: Gastric cancer deals with royalty rates, %
Figure 11: Top Gastric cancer deals by value since 2010
Figure 12: Big pharma - top 50 - Gastric cancer deals 2010 to 2015
Figure 13: Big pharma Gastric cancer deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - Gastric cancer deals 2010 to 2015
Figure 15: Big biotech Gastric cancer deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Global Gastric Cancer Treatment Market - Growth, Trends and Forecasts (2016 - 2021)

Global Gastric Cancer Treatment Market - Growth, Trends and Forecasts (2016 - 2021)

  • $ 4250
  • Industry report
  • October 2016
  • by Mordor Intelligence LLP

The global gastric cancer therapeutics market is expected to grow at a CAGR of XX% during the forecast period 2016-2021. The market was valued at USD XX million in 2015 and is forecasted to reach USD XX ...

Implantable Infusion Pumps Market Analysis & Trends- Application (Cancer Treatment, Cancer Pain, Noncancer Pain, Spasticity, Analgesia, Mixed Sarcoma and Skin Cancers, Gastric Cancer and Diabetes Mellitus) - Forecast to 2025

Implantable Infusion Pumps Market Analysis & Trends- Application (Cancer Treatment, Cancer Pain, Noncancer Pain, Spasticity, Analgesia, Mixed Sarcoma and Skin Cancers, Gastric Cancer and Diabetes Mellitus) - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Implantable Infusion Pumps Market is poised to grow at a CAGR of around 6.3% over the next decade to reach approximately $14.33 billion by 2025. Some of the prominent trends that the market ...

Gastric Cancer  - Epidemiology Forecast To 2023

Gastric Cancer  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Gastric Cancer  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Gastric Cancer  in seven major markets (US, France, Germany, Italy, Spain, UK and ...


Download Unlimited Documents from Trusted Public Sources

Cancer Statistics in the US

  • January 2017
    16 pages
  • Cancer  

  • United States  

    World  

View report >

Colorectal Cancer Statistics in the Netherlands

  • January 2017
    20 pages
  • Colorectal Canc...  

    Hospital  

  • Netherlands  

View report >

Gastric Cancer Statistics in the Netherlands

  • January 2017
    15 pages
  • Gastric Cancer  

  • Netherlands  

    United States  

View report >

Related Market Segments :

Gastric Cancer

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.